Neff wrote “At the recent North American Cystic Fibrosis Conference (NACFC), a key theme of the plenary sessions was the “path to a cure” for the 10% of CF patients who don’t benefit from CF modulators. For those patients who do benefit from modulators, many presenters also considered how better therapies can be developed. Among the many studies cited at the conference, the research effort led by Professor Mads Larsen at the University of Pittsburgh School of Medicine stands out. Their study aimed to identify alternative chloride channels that work similarly to CFTR. The idea is that boosting the function of these alternative channels will recapitulate and strengthen the effects of CFTR modulation.”
Read the article here.